<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250116111232&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20250116111232&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 16 Jan 2025 16:12:33 +0000</lastbuilddate>
<pubDate>Thu, 16 Jan 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>ABE-Mediated Cardiac Gene Silencing via Single AAVs Requires DNA Accessibility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39817340/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Jan 16. doi: 10.1161/CIRCRESAHA.124.325611. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39817340/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39817340</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325611>10.1161/CIRCRESAHA.124.325611</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39817340</guid>
<pubDate>Thu, 16 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Zhanzhao Liu</dc:creator>
<dc:creator>Luzi Yang</dc:creator>
<dc:creator>Yuhan Yang</dc:creator>
<dc:creator>Jiting Li</dc:creator>
<dc:creator>Zhan Chen</dc:creator>
<dc:creator>Congting Guo</dc:creator>
<dc:creator>Qianhao Guo</dc:creator>
<dc:creator>Qiuxuan Li</dc:creator>
<dc:creator>Dongyu Zhao</dc:creator>
<dc:creator>Xiaomin Hu</dc:creator>
<dc:creator>Fei Gao</dc:creator>
<dc:creator>Yuxuan Guo</dc:creator>
<dc:date>2025-01-16</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>ABE-Mediated Cardiac Gene Silencing via Single AAVs Requires DNA Accessibility</dc:title>
<dc:identifier>pmid:39817340</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325611</dc:identifier>
</item>
<item>
<title>EuroThrombosis and EuroVessels (ETEV) 2024</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39816003/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 16:ehae828. doi: 10.1093/eurheartj/ehae828. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39816003/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39816003</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae828>10.1093/eurheartj/ehae828</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39816003</guid>
<pubDate>Thu, 16 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Andrea Rubboli</dc:creator>
<dc:creator>Oliver Schlager</dc:creator>
<dc:date>2025-01-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>EuroThrombosis and EuroVessels (ETEV) 2024</dc:title>
<dc:identifier>pmid:39816003</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae828</dc:identifier>
</item>
<item>
<title>Reply: Implantable Loop Recorders in Patients With Brugada Syndrome: What Is the Appropriate Use in These Patients?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814481/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):e27. doi: 10.1016/j.jacc.2024.10.117.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814481/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814481</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.117>10.1016/j.jacc.2024.10.117</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814481</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Marco Bergonti</dc:creator>
<dc:creator>Giulio Conte</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Implantable Loop Recorders in Patients With Brugada Syndrome: What Is the Appropriate Use in These Patients?</dc:title>
<dc:identifier>pmid:39814481</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.117</dc:identifier>
</item>
<item>
<title>Implantable Loop Recorders in Patients With Brugada Syndrome: What Is the Appropriate Use in These Patients?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814480/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):e25. doi: 10.1016/j.jacc.2024.09.1245.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814480/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814480</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.09.1245>10.1016/j.jacc.2024.09.1245</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814480</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Gregory Dendramis</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implantable Loop Recorders in Patients With Brugada Syndrome: What Is the Appropriate Use in These Patients?</dc:title>
<dc:identifier>pmid:39814480</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.09.1245</dc:identifier>
</item>
<item>
<title>Responder Analyses Can Be Misleading</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814479/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):196-198. doi: 10.1016/j.jacc.2024.11.017.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814479/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814479</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.017>10.1016/j.jacc.2024.11.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814479</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Mary Ross Southworth</dc:creator>
<dc:creator>Mitchell A Psotka</dc:creator>
<dc:creator>Jordan E Pomeroy</dc:creator>
<dc:creator>Norman L Stockbridge</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Responder Analyses Can Be Misleading</dc:title>
<dc:identifier>pmid:39814479</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.017</dc:identifier>
</item>
<item>
<title>Did Finerenone Improve Health Status in the FINEARTS Trial?: A Critical Reevaluation of the Analysis of Patient-Reported Outcomes in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814478/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>Patient-reported health status is an important assessment of patients with heart failure, but current approaches have substantial methodological and analytical limitations. Changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) are commonly presented as a measure of the effect of drugs and devices, most often as the between-group difference in population means or as the odds of showing threshold changes of 5, 10, 15, and 20 points. However, the presentation of mean differences is based...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):190-195. doi: 10.1016/j.jacc.2024.12.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Patient-reported health status is an important assessment of patients with heart failure, but current approaches have substantial methodological and analytical limitations. Changes in the Kansas City Cardiomyopathy Questionnaire (KCCQ) are commonly presented as a measure of the effect of drugs and devices, most often as the between-group difference in population means or as the odds of showing threshold changes of 5, 10, 15, and 20 points. However, the presentation of mean differences is based on statistical assumptions that are routinely violated in most trials. The presentation of threshold changes is based on the belief that a within-patient change in KCCQ of 5 points represents a significant treatment difference across diverse populations and trial settings, but the minimal clinically meaningful difference varies substantially depending on patient characteristics, comorbidities, and trial duration and design, with most values for minimally clinically important difference for KCCQ ranging from 10 to 20 points. Furthermore, the assessment of between-group differences is highly distorted by the assignment of a large proportion of randomized patients with very good health status as having substantially improved even if they showed no change after treatment. Any responder analysis is highly sensitive to differences in variance between the 2 treatment groups and cannot account for the stability of changes in the KCCQ score. The imposition of number-to-treat presentations onto KCCQ scores further compounds the lack of interpretability of reported changes. It is therefore not surprising that trials have reported substantial discrepancies between the effect of treatment on KCCQ and on the risk of hospitalizations for heart failure. In the FINEARTS (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure) trial, finerenone produced an 18% reduction in the risk of hospitalizations for heart failure but yielded uninterpretable and clinically questionable changes in KCCQ, with the small possibility of a modest benefit in &lt;2% of randomized patients. Most physicians are unaware of the critically important methodological concerns summarized in the current paper, and, therefore, may make clinical decisions that hinge on unwarranted impressions of the effects of an intervention on health status.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814478/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814478</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.005>10.1016/j.jacc.2024.12.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814478</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>Muhammad Shariq Usman</dc:creator>
<dc:creator>Frank E Harrell</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Did Finerenone Improve Health Status in the FINEARTS Trial?: A Critical Reevaluation of the Analysis of Patient-Reported Outcomes in Heart Failure</dc:title>
<dc:identifier>pmid:39814478</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.005</dc:identifier>
</item>
<item>
<title>When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814477/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):186-189. doi: 10.1016/j.jacc.2024.12.002.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814477/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814477</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.002>10.1016/j.jacc.2024.12.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814477</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Kevin Damman</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>When Kidney Function Declines But Therapy Still Works: The Case for Nonsteroidal MRA Therapy in Heart Failure</dc:title>
<dc:identifier>pmid:39814477</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.002</dc:identifier>
</item>
<item>
<title>Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814476/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Although an initial decline in eGFR was associated with worse outcomes in patients assigned to placebo, this relationship was not as strong in those treated with finerenone. An early decline in eGFR can be anticipated with finerenone and should not automatically lead to the discontinuation of this disease-modifying therapy (FINEARTS-HF Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure [NCT04435626]; A Multicenter, Randomized,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):173-185. doi: 10.1016/j.jacc.2024.11.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: An initial decline in estimated glomerular filtration rate (eGFR) often leads to reluctance to continue life-saving therapies in patients with heart failure (HF).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The goal of this study was to describe the association between initial decline in eGFR and subsequent clinical outcomes in patients randomized to placebo or finerenone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this prespecified analysis of FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure), we examined the association between initial decline in eGFR (≥15%) from randomization to 1 month and subsequent outcomes in patients assigned to finerenone or placebo. The primary outcome was the composite of total HF events and cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among 5,587 patients with an eGFR measurement at both baseline and 1 month, 1,018 (18.2%) experienced a ≥15% decline in eGFR. The proportion of patients experiencing a ≥15% decline in eGFR was 23.0% with finerenone and 13.4% with placebo (OR: 1.95; 95% CI: 1.69-2.24; P &lt; 0.001). After adjustment, an eGFR decline was associated with a higher risk of the primary outcome in patients assigned to placebo (adjusted rate ratio: 1.50; 95% CI: 1.20-1.89) but not in those assigned to finerenone (adjusted rate ratio: 1.07; 95% CI: 0.84-1.35; P<sub>interaction</sub> = 0.04). By contrast, the efficacy of finerenone was consistent across the range of change in eGFR from baseline to 1 month (P<sub>interaction</sub> = 0.50 for percent change in eGFR), and safety, including hyperkalemia, was similar regardless of an early eGFR decline.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Although an initial decline in eGFR was associated with worse outcomes in patients assigned to placebo, this relationship was not as strong in those treated with finerenone. An early decline in eGFR can be anticipated with finerenone and should not automatically lead to the discontinuation of this disease-modifying therapy (FINEARTS-HF Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure [NCT04435626]; A Multicenter, Randomized, Double-Bline, Parallel-Group, Placebo-Controlled Study to Evaluate the efficacy and safety of finerenone on morbidity and mortality in participants With Heart Failure [NYHA II-IV] and left ventricular ejection fraction ≥40% [EudraCT 2020-000306-29]).</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814476/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814476</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.020>10.1016/j.jacc.2024.11.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814476</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Meike Brinker</dc:creator>
<dc:creator>Patrick Schloemer</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Jon W Mares</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Gerard C M Linssen</dc:creator>
<dc:creator>Jose Francisco Kerr Saraiva</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Richard Troughton</dc:creator>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF: A Prespecified Analysis of FINEARTS-HF</dc:title>
<dc:identifier>pmid:39814476</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.020</dc:identifier>
</item>
<item>
<title>Unentangling Heart Failure From Kidney Outcomes With Finerenone: Insights From the FINEARTS-HF Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814475/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):169-172. doi: 10.1016/j.jacc.2024.11.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814475/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814475</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.024>10.1016/j.jacc.2024.11.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814475</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Sanjay Kaul</dc:creator>
<dc:creator>Swapnil Hiremath</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Unentangling Heart Failure From Kidney Outcomes With Finerenone: Insights From the FINEARTS-HF Trial</dc:title>
<dc:identifier>pmid:39814475</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.024</dc:identifier>
</item>
<item>
<title>A Comprehensive Exploration of FINEARTS-HF: A JACC Theme Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814474/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Jan 21;85(2):103-105. doi: 10.1016/j.jacc.2024.12.004.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814474/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814474</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.004>10.1016/j.jacc.2024.12.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814474</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Theresa McDonagh</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Comprehensive Exploration of FINEARTS-HF: A JACC Theme Issue</dc:title>
<dc:identifier>pmid:39814474</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.004</dc:identifier>
</item>
<item>
<title>Vascular biology and medicine: amyloid-beta alterations in neurocardiovascular diseases and new targets to treat smooth muscle cell dysfunction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814469/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 16;46(3):223-226. doi: 10.1093/eurheartj/ehae878.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814469/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814469</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae878>10.1093/eurheartj/ehae878</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814469</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Vascular biology and medicine: amyloid-beta alterations in neurocardiovascular diseases and new targets to treat smooth muscle cell dysfunction</dc:title>
<dc:identifier>pmid:39814469</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae878</dc:identifier>
</item>
<item>
<title>Six years strong: the transformative journey of the European Society of Cardiology Patient Forum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814468/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 16;46(3):227-228. doi: 10.1093/eurheartj/ehae738.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814468/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814468</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae738>10.1093/eurheartj/ehae738</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814468</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lis Neubeck</dc:creator>
<dc:creator>Inga Drossart</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Six years strong: the transformative journey of the European Society of Cardiology Patient Forum</dc:title>
<dc:identifier>pmid:39814468</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae738</dc:identifier>
</item>
<item>
<title>Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>Osteosarcoma is the most common primary cancer of the bone, with a peak incidence in children and young adults. Using multi-region whole-genome sequencing, we find that chromothripsis is an ongoing mutational process, occurring subclonally in 74% of osteosarcomas. Chromothripsis generates highly unstable derivative chromosomes, the ongoing evolution of which drives the acquisition of oncogenic mutations, clonal diversification, and intra-tumor heterogeneity across diverse sarcomas and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 9:S0092-8674(24)01418-1. doi: 10.1016/j.cell.2024.12.005. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Osteosarcoma is the most common primary cancer of the bone, with a peak incidence in children and young adults. Using multi-region whole-genome sequencing, we find that chromothripsis is an ongoing mutational process, occurring subclonally in 74% of osteosarcomas. Chromothripsis generates highly unstable derivative chromosomes, the ongoing evolution of which drives the acquisition of oncogenic mutations, clonal diversification, and intra-tumor heterogeneity across diverse sarcomas and carcinomas. In addition, we characterize a new mechanism, termed loss-translocation-amplification (LTA) chromothripsis, which mediates punctuated evolution in about half of pediatric and adult high-grade osteosarcomas. LTA chromothripsis occurs when a single double-strand break triggers concomitant TP53 inactivation and oncogene amplification through breakage-fusion-bridge cycles. It is particularly prevalent in osteosarcoma and is not detected in other cancers driven by TP53 mutation. Finally, we identify the level of genome-wide loss of heterozygosity as a strong prognostic indicator for high-grade osteosarcoma.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814020</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.005>10.1016/j.cell.2024.12.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814020</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Jose Espejo Valle-Inclan</dc:creator>
<dc:creator>Solange De Noon</dc:creator>
<dc:creator>Katherine Trevers</dc:creator>
<dc:creator>Hillary Elrick</dc:creator>
<dc:creator>Ianthe A E M van Belzen</dc:creator>
<dc:creator>Sonia Zumalave</dc:creator>
<dc:creator>Carolin M Sauer</dc:creator>
<dc:creator>Mélanie Tanguy</dc:creator>
<dc:creator>Thomas Butters</dc:creator>
<dc:creator>Francesc Muyas</dc:creator>
<dc:creator>Alistair G Rust</dc:creator>
<dc:creator>Fernanda Amary</dc:creator>
<dc:creator>Roberto Tirabosco</dc:creator>
<dc:creator>Adam Giess</dc:creator>
<dc:creator>Alona Sosinsky</dc:creator>
<dc:creator>Greg Elgar</dc:creator>
<dc:creator>Adrienne M Flanagan</dc:creator>
<dc:creator>Isidro Cortés-Ciriano</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution</dc:title>
<dc:identifier>pmid:39814020</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.005</dc:identifier>
</item>
<item>
<title>Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39814019/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>In a genome-wide association study (GWAS) meta-analysis of 688,808 individuals with major depression (MD) and 4,364,225 controls from 29 countries across diverse and admixed ancestries, we identify 697 associations at 635 loci, 293 of which are novel. Using fine-mapping and functional tools, we find 308 high-confidence gene associations and enrichment of postsynaptic density and receptor clustering. A neural cell-type enrichment analysis utilizing single-cell data implicates excitatory,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 10:S0092-8674(24)01415-6. doi: 10.1016/j.cell.2024.12.002. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In a genome-wide association study (GWAS) meta-analysis of 688,808 individuals with major depression (MD) and 4,364,225 controls from 29 countries across diverse and admixed ancestries, we identify 697 associations at 635 loci, 293 of which are novel. Using fine-mapping and functional tools, we find 308 high-confidence gene associations and enrichment of postsynaptic density and receptor clustering. A neural cell-type enrichment analysis utilizing single-cell data implicates excitatory, inhibitory, and medium spiny neurons and the involvement of amygdala neurons in both mouse and human single-cell analyses. The associations are enriched for antidepressant targets and provide potential repurposing opportunities. Polygenic scores trained using European or multi-ancestry data predicted MD status across all ancestries, explaining up to 5.8% of MD liability variance in Europeans. These findings advance our global understanding of MD and reveal biological targets that may be used to target and develop pharmacotherapies addressing the unmet need for effective treatment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39814019/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39814019</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.12.002>10.1016/j.cell.2024.12.002</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39814019</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium. Electronic address: andrew.mcintosh@ed.ac.uk</dc:creator>
<dc:creator>Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Trans-ancestry genome-wide study of depression identifies 697 associations implicating cell types and pharmacotherapies</dc:title>
<dc:identifier>pmid:39814019</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.12.002</dc:identifier>
</item>
<item>
<title>Artificial Intelligence-Guided Lung Ultrasound by Nonexperts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39813064/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this multicenter validation study, THCPs with AI assistance achieved LUS images meeting diagnostic standards compared with LUS experts without AI. This technology could extend access to LUS to underserved areas lacking expert personnel.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 15. doi: 10.1001/jamacardio.2024.4991. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Lung ultrasound (LUS) aids in the diagnosis of patients with dyspnea, including those with cardiogenic pulmonary edema, but requires technical proficiency for image acquisition. Previous research has demonstrated the effectiveness of artificial intelligence (AI) in guiding novice users to acquire high-quality cardiac ultrasound images, suggesting its potential for broader use in LUS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate the ability of AI to guide acquisition of diagnostic-quality LUS images by trained health care professionals (THCPs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this multicenter diagnostic validation study conducted between July 2023 and December 2023, participants aged 21 years or older with shortness of breath recruited from 4 clinical sites underwent 2 ultrasound examinations: 1 examination by a THCP operator using Lung Guidance AI and the other by a trained LUS expert without AI. The THCPs (including medical assistants, respiratory therapists, and nurses) underwent standardized AI training for LUS acquisition before participation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Lung Guidance AI software uses deep learning algorithms guiding LUS image acquisition and B-line annotation. Using an 8-zone LUS protocol, the AI software automatically captures images of diagnostic quality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of THCP-acquired examinations of diagnostic quality according to a panel of 5 masked expert LUS readers, who provided remote review and ground truth validation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The intention-to-treat analysis included 176 participants (81 female participants [46.0%]; mean [SD] age, 63 [14] years; mean [SD] body mass index, 31 [8]). Overall, 98.3% (95% CI, 95.1%-99.4%) of THCP-acquired studies were of diagnostic quality, with no statistically significant difference in quality compared to LUS expert-acquired studies (difference, 1.7%; 95% CI, -1.6% to 5.0%).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this multicenter validation study, THCPs with AI assistance achieved LUS images meeting diagnostic standards compared with LUS experts without AI. This technology could extend access to LUS to underserved areas lacking expert personnel.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05992324.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39813064/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39813064</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4991>10.1001/jamacardio.2024.4991</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39813064</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Cristiana Baloescu</dc:creator>
<dc:creator>John Bailitz</dc:creator>
<dc:creator>Baljash Cheema</dc:creator>
<dc:creator>Ravi Agarwala</dc:creator>
<dc:creator>Madeline Jankowski</dc:creator>
<dc:creator>Onyinyechi Eke</dc:creator>
<dc:creator>Rachel Liu</dc:creator>
<dc:creator>Jason Nomura</dc:creator>
<dc:creator>Lori Stolz</dc:creator>
<dc:creator>Luna Gargani</dc:creator>
<dc:creator>Eren Alkan</dc:creator>
<dc:creator>Tyler Wellman</dc:creator>
<dc:creator>Nripesh Parajuli</dc:creator>
<dc:creator>Andrew Marra</dc:creator>
<dc:creator>Yngvil Thomas</dc:creator>
<dc:creator>Daven Patel</dc:creator>
<dc:creator>Evelyn Schraft</dc:creator>
<dc:creator>James O'Brien</dc:creator>
<dc:creator>Christopher L Moore</dc:creator>
<dc:creator>Michael Gottlieb</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Artificial Intelligence-Guided Lung Ultrasound by Nonexperts</dc:title>
<dc:identifier>pmid:39813064</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4991</dc:identifier>
</item>
<item>
<title>Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39813027/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study, LDL-C and T2D risks were inversely associated across genetic mechanisms for LDL-C variation. Further elucidation of the mechanisms associating low LDL-C risk with increased risk of T2D is warranted.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2025 Jan 15. doi: 10.1001/jamacardio.2024.5072. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Treatment to lower high levels of low-density lipoprotein cholesterol (LDL-C) reduces incident coronary artery disease (CAD) risk but modestly increases the risk for incident type 2 diabetes (T2D). The extent to which genetic factors across the cholesterol spectrum are associated with incident T2D is not well understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the association of genetic predisposition to increased LDL-C levels with incident T2D risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: In this large prospective, population-based cohort study, UK Biobank participants who underwent whole-exome sequencing and genome-wide genotyping were included. Participants were separated into 7 groups with familial hypercholesterolemia (FH), predicted loss of function (pLOF) in APOB or PCSK9 variants, and LDL-C polygenic risk score (PRS) quintiles. Data were collected between 2006 and 2010, with a median follow-up of 13.7 (IQR, 12.9-14.5) years. Data were analyzed from March 1 to November 1, 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURES: LDL-C level, LDL-C PRS, FH, or pLOF variant status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Cox proportional hazards regression models adjusted for age, sex, genotyping array, lipid-lowering medication use, and the first 10 genetic principal components were fitted to assess the association between LDL-C genetic factors and incident T2D and CAD risks.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Among the 361 082 participants, mean (SD) age was 56.8 (8.0) years, 194 751 (53.9%) were female, and mean (SD) baseline LDL-C level was 138.0 (33.6) mg/dL. During the follow-up period, 22 619 (6.3%) participants developed incident T2D and 17 966 (5.0%) developed incident CAD. The hazard ratio for incident T2D was lowest in the FH group (0.65; 95% CI, 0.54-0.77), while the highest risk was in the pLOF group (1.48; 95% CI, 1.18-1.86). The association between LDL-C PRS and incident T2D was 0.72 (95% CI, 0.66-0.79) for very high LDL-C PRS, 0.87 (95% CI, 0.84-0.90) for high LDL-C PRS, 1.13 (95% CI, 1.09-1.17) for low LDL-C PRS, and 1.26 (95% CI, 1.15-1.38) for very low LDL-C PRS. CAD risk increased directly with the LDL-C PRS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study, LDL-C and T2D risks were inversely associated across genetic mechanisms for LDL-C variation. Further elucidation of the mechanisms associating low LDL-C risk with increased risk of T2D is warranted.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39813027/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39813027</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.5072>10.1001/jamacardio.2024.5072</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39813027</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Akshaya Ravi</dc:creator>
<dc:creator>Satoshi Koyama</dc:creator>
<dc:creator>So Mi Jemma Cho</dc:creator>
<dc:creator>Sara Haidermota</dc:creator>
<dc:creator>Whitney Hornsby</dc:creator>
<dc:creator>Patrick T Ellinor</dc:creator>
<dc:creator>Pradeep Natarajan</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Genetic Predisposition to Low-Density Lipoprotein Cholesterol and Incident Type 2 Diabetes</dc:title>
<dc:identifier>pmid:39813027</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.5072</dc:identifier>
</item>
<item>
<title>Using artificial intelligence to spot heart failure from ECGs: is it prime time?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39812702/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Jan 15:ehae906. doi: 10.1093/eurheartj/ehae906. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39812702/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39812702</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae906>10.1093/eurheartj/ehae906</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39812702</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Charalambos Antoniades</dc:creator>
<dc:creator>Kenneth Chan</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Using artificial intelligence to spot heart failure from ECGs: is it prime time?</dc:title>
<dc:identifier>pmid:39812702</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae906</dc:identifier>
</item>
<item>
<title>Assessing and Addressing Cardiovascular and Obstetric Risks in Patients Undergoing Assisted Reproductive Technology: A Scientific Statement From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39811953/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>The use of assisted reproductive technology (ART) is growing, both to assist individuals with infertility and for fertility preservation. Individuals with cardiovascular disease (CVD), or risk factors for CVD, are increasingly using ART. Thus, knowing how to care for patients undergoing ART is important for the cardiovascular clinician. In this scientific statement, we review the ART process and known short-term and long-term risks associated with ART that can adversely affect patients with CVD....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Jan 15. doi: 10.1161/CIR.0000000000001292. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The use of assisted reproductive technology (ART) is growing, both to assist individuals with infertility and for fertility preservation. Individuals with cardiovascular disease (CVD), or risk factors for CVD, are increasingly using ART. Thus, knowing how to care for patients undergoing ART is important for the cardiovascular clinician. In this scientific statement, we review the ART process and known short-term and long-term risks associated with ART that can adversely affect patients with CVD. We review current knowledge on risks from ART for specific cardiac conditions and provide a suggested approach to evaluating and counseling patients with CVD contemplating ART as well as suggested management before and during the ART process. Individuals with CVD are at increased risk for pregnancy complications, and management of this unique population has been discussed previously. The focus of this scientific statement is on ART. Therefore, discussions on risk assessment, counseling, and management of individuals with CVD during pregnancy are limited, and established guidelines are referenced.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39811953/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39811953</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001292>10.1161/CIR.0000000000001292</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39811953</guid>
<pubDate>Wed, 15 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Rina Mauricio</dc:creator>
<dc:creator>Garima Sharma</dc:creator>
<dc:creator>Jennifer Lewey</dc:creator>
<dc:creator>Rose Tompkins</dc:creator>
<dc:creator>Torie Plowden</dc:creator>
<dc:creator>Kathryn Rexrode</dc:creator>
<dc:creator>Mary Canobbio</dc:creator>
<dc:creator>Jenna Skowronski</dc:creator>
<dc:creator>Afshan Hameed</dc:creator>
<dc:creator>Candice Silversides</dc:creator>
<dc:creator>Harmony Reynolds</dc:creator>
<dc:creator>Arthur Vaught</dc:creator>
<dc:creator>American Heart Association Cardiovascular Disease and Stroke in Women and Underrepresented Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Lifelong Congenital Heart Disease and Heart Health in the Young</dc:creator>
<dc:date>2025-01-15</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Assessing and Addressing Cardiovascular and Obstetric Risks in Patients Undergoing Assisted Reproductive Technology: A Scientific Statement From the American Heart Association</dc:title>
<dc:identifier>pmid:39811953</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001292</dc:identifier>
</item>
<item>
<title>Mind the gap: sex-related differences in cardiovascular disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39810050/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 14. doi: 10.1038/s41569-025-01120-7. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39810050/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39810050</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01120-7>10.1038/s41569-025-01120-7</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39810050</guid>
<pubDate>Tue, 14 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Anju Loveridge</dc:creator>
<dc:date>2025-01-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Mind the gap: sex-related differences in cardiovascular disease</dc:title>
<dc:identifier>pmid:39810050</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01120-7</dc:identifier>
</item>
<item>
<title>Engineering extracellular vesicles for therapeutic delivery in ischaemic stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39810049/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 14. doi: 10.1038/s41569-025-01122-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39810049/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39810049</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01122-5>10.1038/s41569-025-01122-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39810049</guid>
<pubDate>Tue, 14 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Lara Anne Birch</dc:creator>
<dc:date>2025-01-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Engineering extracellular vesicles for therapeutic delivery in ischaemic stroke</dc:title>
<dc:identifier>pmid:39810049</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01122-5</dc:identifier>
</item>
<item>
<title>Effective CRISPR modulation of complex non-coding RNA loci</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39810048/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250116111232&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2025 Jan 14. doi: 10.1038/s41569-025-01117-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39810048/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250116111232&v=2.18.0.post9+e462414">39810048</a> | DOI:<a href=https://doi.org/10.1038/s41569-025-01117-2>10.1038/s41569-025-01117-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39810048</guid>
<pubDate>Tue, 14 Jan 2025 06:00:00 -0500</pubDate>
<dc:creator>Francesca Vacante</dc:creator>
<dc:creator>Andrew H Baker</dc:creator>
<dc:date>2025-01-14</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Effective CRISPR modulation of complex non-coding RNA loci</dc:title>
<dc:identifier>pmid:39810048</dc:identifier>
<dc:identifier>doi:10.1038/s41569-025-01117-2</dc:identifier>
</item>





























</channel>
</rss>